Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

OncoTelic

OncoTelic
2015 FOUNDED
PUBLIC STATUS
1-10 EMPLOYEES
MATN STOCK SYMBOL
1 INVESTMENTS
$0.18 SHARE PRICE (As of Thursday Closing)
Description

Mateon Therapeutics Inc is a US-based biopharmaceutical company which is focused on the development of vascular disrupting agents (VDA), for the treatment of cancer. VDA targets the vasculature of cancer tumors and obstructs a tumor's blood supply without disrupting the blood supply to normal tissues. The company is engaged in developing clinical stage investigational drugs that is CA4P and OXi4503. CA4P s a reversible tubulin-binding agent that selectively targets endothelial cells, which make up the interior lining of blood vessel walls in solid tumors; and OXi4503 which is a novel, dual-mechanism VDA, to reduce tumor blood flow and it also forms a potentially anti-proliferative metabolite.

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
PINX
Primary Office
  • 29397 Agoura Road
  • Suite 107
  • Agoura Hills, CA 91301
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore OncoTelic’s full profile, request a free trial.

OncoTelic Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$0.06 - $0.35 $14.9M $0.20 -$0.04 48.7K 83.1M

OncoTelic Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 23,232 2,131 1,991 (6,661)
Revenue 0 0 0
EBITDA (5,244) (2,751) (13,838) (13,741)
Net Income (5,335) (2,737) (13,812) (13,654)
Total Assets 7,529 799 1,172 14,114
Total Debt 488 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

OncoTelic Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore OncoTelic‘s full profile, request access.

Request full access to PitchBook

OncoTelic Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 00000000000 25-Apr-2019 000000000000000000 Drug Discovery 00000 00000 00.0
To view this company’s complete investment and acquisition history, request access »

OncoTelic Subsidiaries (1)

Company Name Industry Location Founded
000000 00000000000 Drug Discovery South San Francisco, CA 0000
To view this company’s complete subsidiary history, request access »

OncoTelic Executive Team (8)

Name Title Board
Seat
Contact
Info
Amit Shah Chief Financial Officer
Chulho Park Ph.D Chief Technology Officer
Vuong Trieu Ph.D Chief Executive Officer & Chairman

5 Former Executives

You’re viewing 3 of 8 executives. Get the full list »

OncoTelic Board Members (2)

Name Representing Role Since Contact
Info
Anthony Maida Ph.D Self Board Member 000 0000
Vuong Trieu Ph.D Self Chief Executive Officer & Chairman 000 0000